非编码RNA在宫颈癌患者预后评估中的价值

doi:10.3877/cma.j.issn.1673-5250.2020.05.017

宫颈癌是妇科最常见的恶性肿瘤之一，其发病率和死亡率均位居全球女性癌症第4位。随着宫颈癌筛查技术的开展及人乳头瘤病毒(HPV)疫苗的投入使用，发达国家宫颈癌发病率呈明显下降趋势。而在发展中国家，由于经济落后及其他原因，宫颈癌发病率下降趋势并不显著。对于宫颈癌术后患者，目前临床上多采用定期监测血清鳞状细胞癌抗原(SCC)、糖类抗原(CA)125等指标评估宫颈癌复发可能性。但是，这些指标单独使用时均存在缺陷，故寻找可更好评估宫颈癌患者预后的生物标志物迫在眉睫。目前已有研究结果显示，非编码RNA(ncRNA)在评估宫颈癌预后中起着重要作用，而微小RNA(miRNA)、长链ncRNA(lncRNA)及环状RNA(circRNA)这3种ncRNA是目前研究热点。笔者拟对miRNA、lncRNA及circRNA这3种ncRNA在宫颈癌患者预后中的评估价值进行阐述。

关键词: 宫颈肿瘤, 微RNAs, RNA, 未翻译, 长链非编码RNA, 环状RNA, 预后, 女(雌)性

Cervical cancer is one of the most common malignant tumors in gynecology, and its morbidity and mortality rank fourth among women′s cancers worldwide. With the development of cervical cancer screening technology and the use of human papillomavirus (HPV) vaccines, the incidence of cervical cancer has decreased significantly in developed countries.While in developing countries, the incidence of cervical cancer has not decreased significantly due to economic backwardness and other reasons. For patients with cervical cancer after surgery, regular monitoring of squamous cell carcinoma antigen (SCC), carbohydrate antigen (CA)125 and other indicators are used in clinical practice to assess the possibility of recurrence of cervical cancer. However, these indicators are flawed when used alone, so it is urgent to find the biomarkers for better assessment of prognosis of patients with cervical cancer. At present, results of studies have shown that non-coding RNA(ncRNA) plays an important role in evaluating prognosis of patients with cervical cancer, and micro RNA (miRNA), long non-coding RNA (lncRNA) and circular RNA (circRNA) are the current research hotspots. In this paper, the evaluation values of miRNA, lncRNA and circRNA in assessment of the prognosis of patients with cervical cancer are reviewed as follows.

Key words: Uterine cervical neoplasms, MicroRNAs, RNA, untranslated, Long non-coding RNA, Circular RNA, Prognosis, Female

[1]	Peng L, Yuan X, Jiang B, et al. LncRNAs: key players and novel insights into cervical cancer[J]. Tumour Biol, 2016, 37(3): 2779-2788. DOI: 10.1007/s13277-015-4663-9.
[2]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492.
[3]	王宁，刘硕，杨雷，等. 2018全球癌症统计报告解读[J/CD]. 肿瘤综合治疗电子杂志，2019, 5(1): 87-97. DOI: 10.12151/JMCM.2019.01-10.
[4]	Cheng Y, Yang S, Shen Y, et al. The role of high-risk human papillomavirus-related long non-coding RNAs in the prognosis of cervical squamous cell carcinoma[J]. DNA Cell Biol, 2020, 39(4): 645-653. DOI: 10.1089/dna.2019.5167.
[5]	Dou X, Zhou Q, Wen M, et al. Long noncoding RNA FOXD2-AS1 promotes the malignancy of cervical cancer by sponging microRNA-760 and upregulating hepatoma-derived growth factor[J]. Front Pharmacol, 2019, 10: 1700. DOI: 10.3389/fphar.2019.01700.
[6]	Salvatici M, Achilarre MT, Sandri MT, et al. Squamous cell carcinoma antigen (SCC-Ag) during follow-up of cervical cancer patients: role in the early diagnosis of recurrence[J]. Gynecol Oncol, 2016, 142(1): 115-119. DOI: 10.1016/j.ygyno.2016.04.029.
[7]	Zhang Y, Na R, Wang X. LncRNA WT1-AS up-regulates p53 to inhibit the proliferation of cervical squamous carcinoma cells[J]. BMC Cancer, 2019, 19(1): 1052. DOI: 10.1186/s12885-019-6264-2.
[8]	Sasamoto N, Babic A, Rosner BA, et al. Development and validation of circulating CA₁₂₅ prediction models in postmenopausal women[J]. J Ovarian Res, 2019, 12(1): 116. DOI: 10.1186/s13048-019-0591-4.
[9]	Foster W. Diagnosing endometriosis: CA₁₂₅ rules in, but not out[J]. BJOG, 2016, 123(11): 1769. DOI: 10.1111/1471-0528.14224.
[10]	Tang X, Liu S, Ding Y, et al. Serum circular FoxO3a serves as a novel prognostic biomarker in squamous cervical cancer[J]. Cancer Manag Res, 2020, 12: 2531-2540. DOI: 10.2147/CMAR.S243329.
[11]	Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm[J]. Cancer Res, 2017, 77(15): 3965-3981. DOI: 10.1158/0008-5472.CAN-16-2634.
[12]	Vishnoi A, Rani S. MiRNA biogenesis and regulation of diseases: an overview[J]. Methods Mol Biol, 2017, 1509: 1-10. DOI: 10.1007/978-1-4939-6524-3_1.
[13]	Reinhart BJ, Slack FJ, Basson M, et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans[J]. Nature, 2000, 403(6772): 901-906. DOI: 10.1038/35002607.
[14]	Wang J, Liu S, Shi J, et al. The role of miRNA in the diagnosis, prognosis, and treatment of osteosarcoma[J]. Cancer Biother Radiopharm, 2019, 34(10): 605-613. DOI: 10.1089/cbr.2019.2939.
[15]	Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review[J]. EMBO Mol Med, 2012, 4(3): 143-159. DOI: 10.1002/emmm.201100209.
[16]	Huang C, Yu M, Yao X. MicroRNA-17 and the prognosis of human carcinomas: a systematic review and Meta-analysis[J]. BMJ Open, 2018, 8(5): e018070. DOI: 10.1136/bmjopen-2017-018070.
[17]	Park S, Kim J, Eom K, et al. MicroRNA-944 overexpression is a biomarker for poor prognosis of advanced cervical cancer[J]. BMC Cancer, 2019, 19(1): 419. DOI: 10.1186/s12885-019-5620-6.
[18]	Wang Q, Qin J, Chen A, et al. Downregulation of microRNA-145 is associated with aggressive progression and poor prognosis in human cervical cancer[J]. Tumour Biol, 2015, 36(5): 3703-3708. DOI: 10.1007/s13277-014-3009-3.
[19]	Chen S, Gao C, Wu Y, et al. Identification of prognostic miRNA signature and lymph node metastasis-related key genes in cervical cancer[J]. Front Pharmacol, 2020, 11: 544. DOI: 10.3389/fphar.2020.00544.
[20]	Wei W, Liu C. Prognostic and predictive roles of microRNA 411 and its target STK17A in evaluating radiotherapy efficacy and their effects on cell migration and invasion via the p53 signaling pathway in cervical cancer[J]. Mol Med Rep, 2020, 21(1): 267-281. DOI: 10.3892/mmr.2019.10826.
[21]	Chi Y, Wang D, Wang J, et al. Long non-coding RNA in the pathogenesis of cancers[J]. Cells, 2019, 8(9): 1015. DOI: 10.3390/cells8091015.
[22]	Hu X, Sood AK, Dang CV, et al. The role of long noncoding RNAs in cancer: the dark matter matters[J]. Curr Opin Genet Dev, 2018, 48: 8-15. DOI: 10.1016/j.gde.2017.10.004.
[23]	Yang M, Wang M, Li X, et al. The role of lncRNAs in signaling pathway implicated in CC[J]. J Cell Biochem, 2019, 120(3): 2703-2712. DOI: 10.1002/jcb.26835.
[24]	Fang Y, Fullwood MJ. Roles, functions, and mechanisms of long non-coding RNAs in cancer[J]. Genomics Proteomics Bioinform, 2016, 14(1): 42-54. DOI: 10.1016/j.gpb.2015.09.006.
[25]	Chandra GS, Nandan TY. Potential of long non-coding RNAs in cancer patients: from biomarkers to therapeutic targets[J]. Int J Cancer, 2017, 140(9): 1955-1967. DOI: 10.1002/ijc.30546.
[26]	王文豪，王卉，郝敏. 宫颈癌与叶酸相关信号通路的研究进展[J/CD]. 中华妇幼临床医学杂志(电子版)，2020，16(2): 245-248. DOI: 10.3877/cma.j.issn.1673-5250.2020.02.018.
[27]	Zhang L, Yao HR, Liu SK, et al. Long noncoding RNA ROR1？AS1 overexpression predicts poor prognosis and promotes metastasis by activating Wnt/β-catenin/EMT signaling cascade in cervical cancer[J]. Eur Rev Med Pharmacol Sci, 2020, 24(6): 2928-2937. DOI: 10.26355/eurrev_202003_20656.
[28]	Zeng J, Ma YX, Liu ZH, et al. LncRNA SNHG7 contributes to cell proliferation, invasion and prognosis of cervical cancer[J]. Eur Rev Med Pharmacol Sci, 2019, 23(21): 9277-9285. DOI: 10.26355/eurrev_201911_19420.
[29]	Wang X, Zhang J, Wang Y. Long noncoding RNA GAS5-AS1 suppresses growth and metastasis of cervical cancer by increasing GAS5 stability[J]. Am J Transl Res, 2019, 11(8): 4909-4921.
[30]	Yang HY, Huang CP, Cao MM, et al. Long non-coding RNA CRNDE may be associated with poor prognosis by promoting proliferation and inhibiting apoptosis of cervical cancer cells through targeting PI3K/AKT[J]. Neoplasma, 2018, 65(6): 872-880. DOI: 10.4149/neo-2018-171225N841.
[31]	Zheng JJ, Du XJ, Wang HP, et al. Long non-coding RNA 00152 promotes cell proliferation in cervical cancer via regulating miR-216b-5p/HOXA1 axis[J]. Eur Rev Med Pharmacol Sci, 2019, 23(9): 3654-3663. DOI: 10.26355/eurrev_201905_17789.
[32]	Wang Y, Lu T, Wang Q, et al. Circular RNAs: crucial regulators in the human body (Review)[J]. Oncol Rep, 2018, 40(6): 3119-3135. DOI: 10.3892/or.2018.6733.
[33]	Wu Q, Li P, Wu M, et al. Deregulation of circular RNAs in cancer from the perspectives of aberrant biogenesis, transport and removal[J]. Front Genet, 2019, 10: 16. DOI: 10.3389/fgene.2019.00016.
[34]	Huang J, Zhou Q, Li Y. Circular RNAs in gynecological disease: promising biomarkers and diagnostic targets[J]. Biosci Rep, 2019, 39(5): BSR20181641. DOI: 10.1042/BSR20181641.
[35]	Kristensen LS, Andersen MS, Stagsted L, et al. The biogenesis, biology and characterization of circular RNAs[J]. Nat Rev Genet, 2019, 20(11): 675-691. DOI: 10.1038/s41576-019-0158-7.
[36]	Song T, Xu A, Zhang Z, et al. CircRNA hsa_circRNA_101996 increases cervical cancer proliferation and invasion through activating TPX2 expression by restraining miR-8075[J]. J Cell Physiol, 2019, 234(8): 14296-14305. DOI: 10.1002/jcp.28128.
[37]	Yu X, Xiao W, Song H, et al. CircRNA_100876 sponges miR-136 to promote proliferation and metastasis of gastric cancer by upregulating MIEN1 expression[J]. Gene, 2020, 748: 144678. DOI: 10.1016/j.gene.2020.144678.
[38]	Mao Y, Zhang L, Li Y. circEIF4G2 modulates the malignant features of cervical cancer via the miR 218/HOXA1 pathway[J]. Mol Med Rep, 2019, 19(5): 3714-3722. DOI: 10.3892/mmr.2019.10032.
[39]	Ou R, Lv J, Zhang Q, et al. circAMOTL1 motivates AMOTL1 expression to facilitate cervical cancer growth[J]. Mol Ther Nucleic Acids, 2020, 19: 50-60. DOI: 10.1016/j.omtn.2019.09.022.

[1]	许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[2]	高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[3]	李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[4]	梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[5]	张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[6]	李伟, 宋子健, 赖衍成, 周睿, 吴涵, 邓龙昕, 陈锐. 人工智能应用于前列腺癌患者预后预测的研究现状及展望[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 541-546.
[7]	陈樽, 王平, 金华, 周美玲, 李青青, 黄永刚. 肌肉减少症预测结直肠癌术后切口疝发生的应用研究[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 639-644.
[8]	关小玲, 周文营, 陈洪平. PTAAR在乙肝相关慢加急性肝衰竭患者短期预后中的预测价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 841-845.
[9]	韩加刚, 王振军. 梗阻性左半结肠癌的治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 450-458.
[10]	刘郁, 段绍斌, 丁志翔, 史志涛. miR-34a-5p 在结肠癌患者的表达及其与临床特征及预后的相关性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 485-490.
[11]	王国强, 张纲, 唐建坡, 张玉国, 杨永江. LINC00839 调节miR-17-5p/WEE1 轴对结直肠癌细胞增殖、凋亡和迁移的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 491-499.
[12]	陈倩倩, 袁晨, 刘基, 尹婷婷. 多层螺旋CT 参数、癌胚抗原、错配修复基因及病理指标对结直肠癌预后的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 507-511.
[13]	曾明芬, 王艳. 急性胰腺炎合并脂肪肝患者CT 与彩色多普勒超声诊断参数与其病情和预后的关联性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 531-535.
[14]	沈炎, 张俊峰, 唐春芳. 预后营养指数结合血清降钙素原、胱抑素C及视黄醇结合蛋白对急性胰腺炎并发急性肾损伤的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 536-540.
[15]	王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Evaluation value of non-coding RNA in prognosis of patients with cervical cancer

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Evaluation value of non-coding RNA in prognosis of patients with cervical cancer